0001562180-24-000581.txt : 20240124
0001562180-24-000581.hdr.sgml : 20240124
20240124165028
ACCESSION NUMBER: 0001562180-24-000581
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20240122
FILED AS OF DATE: 20240124
DATE AS OF CHANGE: 20240124
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Jones David Scott
CENTRAL INDEX KEY: 0001779458
ORGANIZATION NAME:
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 000-51122
FILM NUMBER: 24557043
MAIL ADDRESS:
STREET 1: C/O EYEPOINT PHARMACEUTICALS, INC.,
STREET 2: 480 PLEASANT STREET, SUITE A210
CITY: WATERTOWN
STATE: MA
ZIP: 02472
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: EyePoint Pharmaceuticals, Inc.
CENTRAL INDEX KEY: 0001314102
STANDARD INDUSTRIAL CLASSIFICATION: LABORATORY ANALYTICAL INSTRUMENTS [3826]
ORGANIZATION NAME: 08 Industrial Applications and Services
IRS NUMBER: 262774444
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 480 PLEASANT STREET
STREET 2: SUITE B300
CITY: WATERTOWN
STATE: MA
ZIP: 02472
BUSINESS PHONE: 617-926-5000
MAIL ADDRESS:
STREET 1: 480 PLEASANT STREET
STREET 2: SUITE B300
CITY: WATERTOWN
STATE: MA
ZIP: 02472
FORMER COMPANY:
FORMER CONFORMED NAME: pSivida Corp.
DATE OF NAME CHANGE: 20080619
FORMER COMPANY:
FORMER CONFORMED NAME: pSivida LTD
DATE OF NAME CHANGE: 20050111
4
1
primarydocument.xml
PRIMARY DOCUMENT
X0508
4
2024-01-22
false
0001314102
EyePoint Pharmaceuticals, Inc.
EYPT
0001779458
Jones David Scott
C/O EYEPOINT PHARMACEUTICALS, INC.
480 PLEASANT STREET
WATERTOWN
MA
02472
false
true
false
false
SVP & Chief Commercial Officer
false
Common Stock
2024-01-22
4
M
false
28750.00
10.13
A
66712.00
D
Common Stock
2024-01-22
4
M
false
5416.00
11.47
A
72128.00
D
Common Stock
2024-01-22
4
S
false
5416.00
22.2373
D
66712.00
D
Common Stock
2024-01-22
4
S
false
28750.00
22.6871
D
37962.00
D
Common Stock
2024-01-23
4
M
false
400.00
12.90
A
38362.00
D
Common Stock
2024-01-23
4
M
false
500.00
3.26
A
38862.00
D
Common Stock
2024-01-23
4
S
false
400.00
25.00
D
38462.00
D
Common Stock
2024-01-23
4
S
false
500.00
25.00
D
37962.00
D
Stock Option (Right to Buy)
11.47
2024-01-22
4
M
false
5416.00
0.00
D
2031-11-01
Common Stock
5416.00
4584.00
D
Stock Option (Right to Buy)
10.13
2024-01-22
4
M
false
28750.00
0.00
D
2032-02-09
Common Stock
28750.00
31250.00
D
Stock Option (Right to Buy)
12.90
2024-01-23
4
M
false
400.00
0.00
D
2030-02-28
Common Stock
400.00
24225.00
D
Stock Option (Right to Buy)
3.26
2024-01-23
4
M
false
500.00
0.00
D
2033-01-05
Common Stock
500.00
91155.00
D
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $22.00 to $23.00. The reporting person undertakes to provide EyePoint Pharmaceuticals Inc., any security holder of EyePoint Pharmaceuticals Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $22.00 to $23.04. The reporting person undertakes to provide EyePoint Pharmaceuticals Inc., any security holder of EyePoint Pharmaceuticals Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
The option to purchase will vest and become exercisable as follows: 25% at November 1st, 2022 and the remainder ratably, on a monthly basis, over the remaining three years.
The option to purchase will vest and become exercisable as follows: 25% at February 9th, 2023 and the remainder ratably, on a monthly basis, over the remaining three years.
The option to purchase vests and becomes exercisable ratably in forty-eight monthly installments which began March 28, 2020
The option to purchase vests and becomes exercisable as follows: 25% at January 6th, 2024 and the remainder ratably, on a monthly basis, over the remaining three years.
/s/ Ron Honig, Attorney-in-Fact
2024-01-24